98%
921
2 minutes
20
Introduction: Spinal cord stimulation (SCS) is a commonly utilized therapy for the treatment of neuropathic pain conditions. The Neurostimulation Appropriateness Consensus Committee (NACC) has recommended that the placement of percutaneous SCS leads be performed in an awake patient capable of providing feedback. It is not currently known how commonly this recommendation is adhered to by physicians in clinical practice. This article presents the findings of a survey designed to answer this important question.
Methods: We conducted a survey of the active membership of the American Society of Regional Anesthesia and Pain Medicine (ASRA) and the Spine Intervention Society (SIS) regarding practice patterns with SCS therapy. We analyzed the percent of respondents who indicated that they use deep sedation and general anesthesia during SCS placement as well as any reported complications.
Results: Many practitioners frequently utilize deep sedation as well as general anesthesia when performing SCS implants. Our findings demonstrate that 77% of physicians reported that they utilize deep sedation for permanent SCS implants at times, and 45% of physicians reported the use of general anesthesia for 10 kHz implants. Additionally, 94% of physicians reported that they have never had a complication related to the use of general anesthesia for a spinal cord stimulator placement.
Conclusions: This survey provides initial data on SCS practices among a large cohort of clinicians who utilize SCS. SCS lead placement under deep sedation and general anesthesia appears to be common practice for many physicians who perform implants. This survey should stimulate further research on this topic, given that the current safety guidelines and the rate of physicians reporting the use of deep sedation and general anesthesia for spinal cord stimulator placement remain at odds.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586060 | PMC |
http://dx.doi.org/10.1007/s40122-021-00332-2 | DOI Listing |
Vet Anaesth Analg
July 2025
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Objective: To determine the use of Air-Test in ventilated, anaesthetized dogs for evaluating oxygen uptake and to determine its potential utility in guiding the decision to perform an alveolar recruitment manoeuvre (ARM).
Study Design: Retrospective cohort study.
Animals: A total of 25 client-owned dogs undergoing general anaesthesia.
Remimazolam is an ultrashort-acting benzodiazepine approved for procedural sedation in 2020 by the US Food and Drug Administration; however, dosing information originating from the US is limited. No existing literature details infusion rates of remimazolam delivered by manually adjusted infusion pumps. This case report describes the administration of manually infused remimazolam to an 86-year-old man for the surgical extraction of third molars under procedural sedation.
View Article and Find Full Text PDFWe report a rare case in which the inflation lumen at the tip of an endotracheal tube (ETT) was open, leading to intraoperative air leakage and cuff deflation. A patient with Down syndrome undergoing planned dental treatment under general anesthesia was induced and nasally intubated with a cuffed ETT that was then inflated with 5 mL of air. Soon thereafter, it was noted that the pilot balloon was deflated and filled with water droplets.
View Article and Find Full Text PDFAnesth Prog
September 2025
Objective: We aimed to investigate the differences in the lengths and shapes of several preformed nasotracheal tubes (NTTs) among different manufacturers and compare our findings with a previous report.
Methods: Using reference points at the tube tip, the proximal edge of the cuff, and the flexion point, we measured tube lengths for NTTs with inner diameters of 6.5, 7.
Few reports exist in dentistry about the use of general anesthesia in children after liver transplant. In this paper, we report our experience utilizing general anesthesia for oral surgery in a 9-year-old girl who had undergone living donor liver transplantation. She was diagnosed with hepatoblastoma at 4 months of age and underwent a living donor liver transplant at 7 months of age.
View Article and Find Full Text PDF